Greenphire References Capped?

Access even more references from these marketplace competitors

  • 4.7 / 5.0 (4109)
    Verified251+ References
  • 4.7 / 5.0 (4032)
    Premium272+ References
  • 4.7 / 5.0 (4144)
    Premium351+ References

Greenphire

Verified
Read 28 Greenphire reviews and testimonials from customers, explore 29 case studies and customer success stories, and watch 2 customer videos to see why companies chose Greenphire as their Clinical Trial Management Software

Greenphire is the leader in global clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials

Show more
Customer Rating Review Scorebased on 1517 reference ratings
4.8/5.0 (1517)
  • Top Performer 2025 2025
    Summer 2025Top PerformerClinical Trial Management Software

28Testimonials

  • “We are so glad we made the decision to implement the ClinCard solution. The automated process has allowed us to focus on the most important part of our work, the participants and our research.”

27 more testimonialscurrently locked

29 Case Studies

  • Nivalis Therapeutics Improves the Clinical Trial Experience for Patients and Investigators with an End-to-End Payment Solution

28 more case studiescurrently locked

2 Customer Videos

1 more videoscurrently locked

Additional Greenphire Information & Resources

Read Greenphire Reviews, Testimonials & Customer References from 28 real Greenphire customers.

Browse Greenphire Case Studies, Customer Success Stories, & Customer References from 29 businesses that use Greenphire.

Watch Greenphire Customer Videos to learn why 2 businesses chose Greenphire.